Effect of Pioglitazone on Visfatin Expression in 3T3-L1 Adipocytes and SD Rats

REFERENCES

• O'Rahilly S. Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997; 314:955–959.
   Google Scholar
• Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229–234.
   PubMed Web of Science ®Google Scholar
• Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106:286–288.
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415–1428.
   PubMed Web of Science ®Google Scholar
• Zigman JM, Nakano Y, Coppari R, Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005; 115:3564–3572.
   PubMed Web of Science ®Google Scholar
• Ross R, Freeman J, Hudson R, Janssen I. Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab 2002; 87:5044–5051.
   PubMed Web of Science ®Google Scholar
• Jin H, Jiang B, Tang J, Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008; 79:412–418.
   PubMed Web of Science ®Google Scholar
• Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 2005; 19:547–566.
   PubMed Web of Science ®Google Scholar
• Zahorska-Markiewicz B, Janowska J, Olszanecka-Glinianowicz M, Zurakowski A. Serum concentrations of TNF-alpha and soluble TNF-alpha receptors in obesity. Int J Obes 2000; 24:1392–1395.
   PubMed Web of Science ®Google Scholar
• Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Janowska J, Zurakowski A. Serum concentrations of nitric oxide, TNF-alpha and TNF soluble receptors in women with overweight and obesity. Metabolism 2004; 53:1268–1273.
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426–430.
   PubMed Web of Science ®Google Scholar
• Berndt J, Klöting N, Kralisch S, Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54:2911–2916.
   PubMed Web of Science ®Google Scholar
• Chen MP, Chung FM, Chang DM, Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91:295–299.
   PubMed Web of Science ®Google Scholar
• Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. Clin Endocrinol Metab 2006; 91:1578–1581.
   Google Scholar
• Jian WX, Luo TH, Gu YY, The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med 2006; 23:967–973.
   PubMed Web of Science ®Google Scholar
• López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55:2871–2875.
   PubMed Web of Science ®Google Scholar
• Chen CC, Li TC, Li CI, The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007; 56:1216–1220.
   PubMed Web of Science ®Google Scholar
• Dogru T, Sonmez A, Tasci I, Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76:24–29.
   PubMed Web of Science ®Google Scholar
• Krzysik-Walker SM, Ocón-Grove OM, Maddineni SR, Hendricks GL 3rd, Ramachandran R. Is visfatin an adipokine or myokine? Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens. Endocrinology 2008; 149:1543–1550.
   PubMed Web of Science ®Google Scholar
• Jung HS, Youn BS, Cho YM, The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 2005; 54:314–320.
   PubMedGoogle Scholar
• Van Wijk JP, de Koning EJ, Castro Cabezas M, Rabelink TJ. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 2005; 28:844–849.
   PubMed Web of Science ®Google Scholar
• Choi KC, Ryu OH, Lee KW, Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005; 336:747–753.
   PubMed Web of Science ®Google Scholar
• Kralisch S, Klein J, Lossner U, Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005; 185:R1–8.
   PubMed Web of Science ®Google Scholar
• Hammarstedt A, Pihlajamäki J, Rotter Sopasakis V, Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006; 91:1181–1184.
   PubMed Web of Science ®Google Scholar
• Erdem G, Dogru T, Tasci I, The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 82:214–218.
   PubMed Web of Science ®Google Scholar
• Fruhbeck G, Bome-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 280:E827–847.
   PubMed Web of Science ®Google Scholar
• Barac A, Campia U, Matuskey LA, Lu L, Panza JA. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Am J Cardiol 2008; 101:980–985.
   Google Scholar
• Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89:4312–4319.
   PubMed Web of Science ®Google Scholar
• Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 2006; 291:E1100–1105.
   Google Scholar
• Li L, Yang G, Shi S, Yang M, Liu H, Boden G. The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo. Cytokine 2009; 45:12–19.
   PubMed Web of Science ®Google Scholar